109193 ⎘
Structure or type of the nucleic acid; Chemical structure; Nature of the modification Conjugate
Serpina1 iRNA compositions and methods of use thereof
#902Processes for preparing phosphorodiamidate morpholino oligomers
#903RENAL CLEARABLE DRUG DELIVERING NANOPARTICLES AND METHODS OF USE THEREFOR
#904Method of modulating the number and the distribution of tumor-infiltrating leukocytes in tumors
#905Therapeutic agent for treating cancer comprising anti-miRNA-albumin composite
#906Method of delivering genes and drugs to a posterior segment of an eye
#907Oligonucleotides for inducing paternal UBE3A expression
#908SELECTIVE ANTISENSE COMPOUNDS AND USES THEREOF
#909COMPOSITIONS AND METHODS FOR MODULATING PKK EXPRESSION
#910Compounds and methods for reducing ATXN2 expression
#911MODULATION OF APOLIPOPROTEIN CIII (APOCIII) EXPRESSION
#912COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION
#913Oligonucleotides for reduction of PD-L1 expression
#914Compositions and methods for the treatment of hypercholesterolemia
#915EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
#916Gene silencing
#917Oligonucleotide Probes and Uses Thereof
#918Complement component C5 iRNA compositions and methods of use thereof
#919LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS
#920Oligomers and oligomer conjugates
#921Modified L-Nucleic Acid
#922Oligonucleotides for modulating Tau expression
#923Capped cyclodextrin-hydrophobic moiety conjugate, cyclodextrin supramolecular polymer, and cyclodextrin-siRNA complex and method of synthesis thereof
#924PEG-ACS/M-siRNA nanocomposite, application thereof, and method for reducing histamine content during fishmeal storage
#925Aptamers for personal care applications
#926Reduced size self-delivering RNAI compounds
#9273′ end caps for RNAi agents for use in RNA interference
#928Nucleic acid constructs and methods of using the same
#929Chemically-modified siRNA
#930METHODS FOR TREATING OR PREVENTING OPHTHALMOLOGICAL CONDITIONS
#931High temperature selection of nucleotide-supported carbohydrate vaccines and resulting glycosylated oligonucleotides
#932Conjugated antisense compounds and their use
#933Compositions and methods for inhibiting gene expression of factor XII
#934METHODS FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASES USING TRANSTHYRETIN (TTR) iRNA COMPOSITIONS
#935Anti-ARID3a treatments for inflammatory disorders
#936Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
#937SELECTIVE ANTISENSE COMPOUNDS AND USES THEREOF
#938EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
#939TNF-alpha-binding aptamer, and therapeutic use for same
#940ORGANIC COMPOSITIONS TO TREAT HSF1-RELATED DISEASES
#941Serpina1 iRNA compositions and methods of use thereof
#942Double-stranded nucleic acid inhibitor molecules modified with Tm-increasing nucleotides
#943Carrier Nanoparticles And Related Compositions, Methods And Systems
#944Oligonucleotides for inducing paternal UBE3A expression
#945RNAi constructs for inhibiting ASGR1 expression and methods of use thereof
#946Antisense oligonucleotides
#947Antiviral agents
#948Compounds and methods for enhanced cellular uptake
#949POLYMER-BASED NANOPARTICLES, RELATED FORMULATIONS METHODS, AND APPARATUS
#950Angiotensinogen (AGT) iRNA compositions and methods of use thereof
#951Nucleic Acid Complexes
#952TMPRSS6 iRNA compositions and methods of use thereof
#953Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene
#954CAMK2D antisense oligonucleotides and uses thereof
#955Antisense molecules and methods for treating pathologies
#956Photoreversible acylation reagents
#957GLYCOCONJUGATES OF RNA INTERFERENCE AGENTS
#958Method of treating cancer
#959Targeting ligands
#960Compositions and methods for correcting limb girdle muscular dystrophy type 2C using exon skipping
#961Modulators of DNM2 expression
#962Modified double-stranded RNA agents
#963Modified double-stranded RNA agents
#964Modulation of prekallikrein (PKK) expression
#965RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
#966Organic compositions to treat APOC3-related diseases
#967Nucleic acid conjugates and uses thereof
#968COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE
#969TMPRSS6 iRNA compositions and methods of use thereof
#970Anti-TNF compounds
#971Targeting Ligands For Therapeutic Compounds
#972COMPOUNDS AND METHODS FOR REDUCING TAU EXPRESSION
#973Oligonucleotides, compositions and methods thereof
#974Natural cryptic exon removal by pairs of antisense oligonucleotides
#975ANTISENSE POLYNUCLEOTIDES TO INDUCE EXON SKIPPING AND METHOD OF TREATING DYSTROPHIES
#976RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
#977POLYNUCLEOTIDE CONSTRUCTS HAVING AN AUXILIARY MOIETY NON-BIOREVERSIBLY LINKED TO AN INTERNUCLEOSIDE PHOSPHATE OR PHOSPHOROTHIOATE
#978RNA/DNA HYBRID NANOPARTICLES MODIFIED WITH SINGLE STRANDED RNA TOEHOLDS AND USES THEREOF
#979Polyplex of double-stranded RNA and polymeric conjugate
#980Aptamer therapeutics useful in the treatment of complement-related disorders
#981Conjugated oligonucleotides
#982Micro-RNA Delivery Compositions, Devices, and Methods
#983Exon skipping compositions for treating muscular dystrophy
#984Targeted nucleic acid conjugate compositions
#985Inhibitory RNA-based therapeutics targeting ANLN for cancer treatment
#986Targeting MicroRNAs for Metabolic Disorders
#987Compositions and methods for inhibiting expression of the ALAS1 gene
#988MODIFIED TGF-BETA OLIGONUCLEOTIDE FOR USE IN A METHOD OF PREVENTING AND/OR TREATING AN OPHTHALMIC DISEASE
#989MicroRNA Compounds and Methods for Modulating MIR-122
#990Oligomer-conjugate complexes and their use
#991Modulating apolipoprotein (a) expression
#992CARBOHYDRATE CONJUGATED RNA AGENTS AND PROCESS FOR THEIR PREPARATION
#993SINGLE-STRANDED RNAI OLIGONUCLEOTIDES TARGETING APOC-III
#994Oligonucleotide analogues targeting human LMNA
#995Universal enzyme responsive linker for assembling ligands on DNA functionalized nanomaterials
#996ISATOIC ANHYDRIDE DERIVATIVES AND APPLICATIONS THEREOF
#997Compositions and methods for inhibiting expression of TMPRSS6 gene
#998Single-stranded oligonucleotide
#999Nucleic acid linked to a trivalent glycoconjugate
#1000COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE LECT2 GENE
#1001Glycosylated oligonucleotides that mimic the HIV-1 epitope of neutralizing monoclonal antibody 2G12
#1002Complex containing oligonucleotide having immunopotentiating activity and use thereof
#1003Oligomers
#1004Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infection
#1005METHOD OF PRODUCING INFERTILE FISH AND EGG-PRODUCING AQUATIC ANIMALS AND OF DELIVERING COMPOUNDS INTO EGGS AND EMBRYOS
#1006DNA aptamers specific to CD2000R1 and their therapeutic uses
#1007Defined multi-conjugate oligonucleotides
#1008RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL3), and methods of use
#1009RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)
#1010Polynucleotides containing a morpholino linker
#1011Nanoparticle to target cancer
#1012Methods for treating hypercholesterolemia
#1013Therapeutic strategies for ovarian cancer: AMHR2-RNA aptamer
#1014LIPID ENCAPSULATING INTERFERING RNA
#1015Modulation of angiopoietin-like 3 expression
#1016SIRNA, PHARMACEUTICAL COMPOSITION AND CONJUGATE WHICH CONTAIN SIRNA, AND USES THEREOF
#1017RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
#1018Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#1019POLYNUCLEOTIDE-POLY(DIOL) CONJUGATES, PROCESS OF PREPARATION AND USES THEREOF
#1020ANTISENSE OLIGONUCLEOTIDES FOR MODULATING HTRA1 EXPRESSION
#1021Nucleic acid conjugate
#1022Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
#1023COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION
#1024LNA-G Process
#1025Gene/carrier complex for preventing or treating inflammatory diseases
#1026Method of producing cells resistant to HIV infection
#1027COMPOSITIONS AND METHODS FOR MODULATION OF SMN2 SPLICING IN A SUBJECT
#1028High density lipoprotein binding protein (Hdlbp/Vigilin) iRNA compositions and methods of use thereof
#1029RNAi-Mediated Inhibition of Tumor Necrosis Factor Alpha-Related Conditions
#1030Targeting glioblastoma stem cells through the TLX-TET3 axis
#1031Phosphonate-drug conjugates
#1032Polynucleotide agents targeting factor XII (hageman factor) (F12) and methods of use thereof
#1033Compositions and methods for modulating angiopoietin-like 3 expression
#1034Dual molecular delivery of oligonucleotides and peptide containing conjugates
#1035RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
#1036RNAi agents for inhibiting expression of alpha-ENaC and methods of use
#1037Anti-ADAM33 oligonucleotides and related methods
#1038DOUBLE-STRANDED OLIGONUCLEOTIDES
#1039Oligo-guanidines based cellular transporter comprising heterocyclic rings with hydrophobic and/or lipophilic groups at N-terminal for effective delivery of nonpenetrable cargos in-vitro and in-vivo
#1040Carrier nanoparticles and related compositions, methods and systems
#1041Polynucleotide agents targeting programmed cell death 1 ligand 1 (PD-L1) and methods of use thereof
#1042RNA interference in dermal and fibrotic indications
#1043Methods and compositions for managing vascular conditions
#1044RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
#1045Methods and compositions for delivery of polynucleotides
#1046Organic compositions to treat beta-ENaC-related diseases
#1047MicroRNA Compounds and Methods for Modulating MIR-21 Activity
#1048Method of isolation of polypeptide-aptamer-polymer conjugates
#1049Magnetic particle conjugates and methods of activating cell signaling
#1050Serpina1 iRNA compositions and methods of use thereof
#1051Use of microRNA-146A and nanoceria conjugate to improve wound healing and promote tissue regeneration
#1052Compositions with improved intravitreal half-life and uses thereof
#1053SPLICE MODULATING OLIGONUCLEOTIDES THAT INHIBIT CANCER
#1054Antitumor drug delivery formulation
#1055siRNA compositions that specifically downregulate expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD)
#1056Antisense Polynucleotides to Induce Exon Skipping and Method of Treating Dystrophies
#1057Targeted self-assembly of functionalized carbon nanotubes on tumors
#1058Fatty acids and their use in conjugation to biomolecules
#1059COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION
#1060Methods of treatment using antisense oligomers and conjugates targeting PCSK9
#1061Manufacture of antisense oligomers and conjugates targeting PCSK9
#1062STAT3 inhibitors and uses thereof
#1063Immunostimulating-toxic RNA in alkaline earth metal formulation
#1064Linkage modified oligomeric compounds
#1065POLYNUCLEOTIDES HAVING BIOREVERSIBLE GROUPS
#1066TARGETED THERAPEUTIC NUCLEOSIDES AND THEIR USE
#1067Methods of agent delivery into eggs and embryos of egg-producing aquatic animals for drug screening, agent toxicity assay and production of infertile fish
#1068Micelle composition for nucleic acid delivery using temperature-sensitive polymer and method for producing same
#1069TLR MODULATORS AND METHODS OF USE
#1070Method of producing infertile fish and egg-producing aquatic animals and of delivering compounds into eggs and embryos
#1071Sterol regulatory element binding protein (SREBP) chaperone (SCAP) iRNA compositions and methods of use thereof
#1072Compositions and methods for modulating apolipoprotein (a) expression
#1073Compositions and methods for modulating apolipoprotein C-III expression
#1074RNAi CONJUGATES, PARTICLES AND FORMULATIONS THEREOF
#1075Compounds and methods for modulation of DUX4
#1076Amphiphilic dendrimers complexed with siRNA for treatment of cancer
#1077METHODS FOR THE TREATMENT OF ALOPECIA AREATA UTILIZING GENE MODULATION APPROACHES
#1078Universal enzyme responsive linker for assembling ligands on DNA functionalized nanomaterials
#1079Compositions and methods for treating HIV-associated neurocognitive disorders
#1080Oligonucleotide conjugates
#1081COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS
#1082RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
#1083Block copolymers
#1084Compounds and methods for trans-membrane delivery of molecules
#1085Compositions and methods for regulation of gene expression with, and detection of, folinic acid and folates
#1086Modified TGF-beta oligonucleotides
#1087Compositions and methods for inhibiting gene expression of Hif2alpha
#1088Brush polymer-assisted compaction of oligonucleotides
#1089Multimeric oligonucleotides having decreased kidney clearance
#1090Functionally-modified oligonucleotides and subunits thereof
#1091SITE-SPECIFIC DELIVERY OF NUCLEIC ACIDS BY COMBINING TARGETING LIGANDS WITH ENDOSOMOLYTIC COMPONENTS
#1092Antisense oligomers targeting PCSK9
#1093XANTHINE DEHYDROGENASE (XDH) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1094Multi-targeted single entity conjugates
#1095Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (PNPLA3) and methods of use thereof
#1096COMPOUNDS AND METHODS FOR MODULATING TARGET NUCLEAR AND SUB-NUCLEAR NUCLEIC ACID MOLECULES IN CELLS AND ANIMALS
#1097Micromirs
#1098Compositions and methods for inhibiting expression of RRM2 genes
#1099Glucokinase (GCK) iRNA compositions and methods of use thereof
#1100Compositions and methods for inhibiting gene expression of LPA
#1101Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use
#1102Nucleic acid functionalized nanoparticles for therapeutic applications
#1103Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
#1104Modified L-Nucleic Acid
#1105Modified CRISPR RNA and modified single CRISPR RNA and uses thereof
#1106Targeting microRNAs for metabolic disorders
#1107Antisense molecules and methods for treating pathologies
#1108DIBLOCK COPOLYMERS AND POLYNUCLEOTIDE COMPLEXES THEREOF FOR DELIVERY INTO CELLS
#1109Carrier nanoparticles and related compositions, methods and systems
#1110Polynucleotide agents targeting angiotensinogen (AGT) and methods of use thereof
#1111SDF-1 Binding Nucleic Acids
#1112ORGANIC COMPOSITIONS TO TREAT KRAS-RELATED DISEASES
#1113RNAi inhibition of alpha-ENaC expression
#1114Compounds and methods for increasing antisense activity
#1115CARBON MATERIAL DELIVERY SYSTEMS AND METHODS
#1116Methods for modulating expression of C9ORF72 antisense transcript
#1117Compositions and methods for inhibiting expression of the LECT2 gene
#1118Modified oligonucleotides and methods of use
#1119MicroRNA initiated DNAzyme motor operating in living cells
#1120Site-Specific DNA-Doxorubicin Conjugates Display Enhanced Cytotoxicity to Breast Cancer Cells
#1121Antisense compounds targeting genes associated with cystic fibrosis
#1122Single-stranded nucleic acid molecule having delivery function and gene expression regulating ability
#1123Cocaine aptamer and method for detecting cocaine using the same
#1124Stereospecific Phosphorothioate LNA
#1125Poly(β-amino ester)-co-polyethylene glycol (PEG-PBAE-PEG) polymers for gene and drug delivery
#1126Isatoic anhydride derivatives and applications thereof
#1127Compounds and methods for modulating TMPRSS6 expression
#1128Short interfering nucleic acid (siNA) compositions
#1129Organic compositions to treat EPAS1-related diseases
#1130TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1131MODIFIED TGF-BETA2 OLIGONUCLEOTIDES
#1132Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
#1133Polyvalent RNA-nanoparticle compositions
#1134POLYNUCLEOTIDE-POLY(DIOL) CONJUGATES, PROCESS OF PREPARATION AND USES THEREOF
#1135Compositions and methods for correcting limb girdle muscular dystrophy type 2C using exon skipping
#1136Single-stranded RNAi agents containing an internal, non-nucleic acid spacer
#1137CD38 ligand-drug conjugates for targeted cancer therapy
#1138CD117 ligand-drug conjugates for targeted cancer therapy
#1139MCP-1 binding nucleic acids
#1140Particle-nucleic acid conjugates and therapeutic uses related thereto
#1141Therapeutic nanoparticles and methods of use thereof
#1142Compositions and methods for modulating Tau expression
#1143HER2 aptamer-anticancer drug complex for cancer cell chemotherapy
#1144HER2 aptamer-anticancer drug complex for cancer cell chemotherapy
#1145Compositions and methods for modulating TTR expression
#1146TISSUE SPECIFIC MARKERS FOR PREOPERATIVE AND INTRAOPERATIVE LOCALIZATION AND VISUALIZATION OF TISSUE
#1147ANTISENSE POLYNUCLEOTIDES TO INDUCE EXON SKIPPING AND METHODS OF TREATING DYSTROPHIES
#1148Compositions and methods for inhibiting expression of the ALAS1 gene
#1149TARGETING OLIGONUCLEOTIDES AND USES THEREOF TO MODULATE GENE EXPRESSION
#1150APTAMER THERAPEUTICS USEFUL IN THE TREATMENT OF COMPLEMENT-RELATED DISORDERS
#1151Compositions and methods for inhibiting gene expression of factor XII
#1152Disulfide-containing alkyne linking agents
#1153LNA OLIGONUCLEOTIDES WITH ALTERNATING FLANKS
#1154Compositions for modulating expression of C9ORF72 antisense transcript
#1155Hyperbranched polymers and polyplexes and DNA or RNA delivery systems including the same
#1156LNA Gapmer Oligonucleotides Comprising Chiral Phosphorothioate Linkages
#1157EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
#1158Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#1159ANTISENSE COMPOUNDS AND USES THEREOF
#1160Antisense oligonucleotides for modulating HTRA1 expression
#1161COMPOSITIONS AND METHODS
#1162EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
#1163EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
#1164EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
#1165TMPRSS6 iRNA compositions and methods of use thereof
#1166Nucleic acid, medical nanoparticle, and pharmaceutical composition thereof
#1167Conjugated antisense compounds and their use
#1168siRNA compositions that specifically downregulate expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD)
#1169Poly oligomer compound with biocleavable conjugates
#1170METHOD AND COMPOSITION FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS
#1171METHODS FOR TREATING HYPERCHOLESTEROLEMIA
#1172RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
#1173Nucleic acid complexes
#1174Inhibitory oligonucleotide and use thereof
#1175LONG ACTING PHARMACEUTICAL COMPOSITIONS FOR HEPATITIS C
#1176Organic compositions to treat Beta-ENaC-related diseases
#1177Modulation of prekallikrein (PKK) expression
#1178Modified TGF-beta oligonucleotide for use in a method of preventing and/or treating an ophthalmic disease
#1179Combination long acting compositions and methods for Hepatitis C
#1180Anti-TNF compounds
#1181METHODS AND COMPOSITIONS FOR INHALATION DELIVERY OF CONJUGATED OLIGONUCLEOTIDE
#1182Compositions and methods for inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) gene expression
#1183RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
#1184Organic compositions to treat HSF1-related diseases
#1185Dnazyme-nanoparticle conjugates and methods of use thereof
#1186Compositions for enhancing targeted gene editing and methods of use thereof
#1187RNA interference compositions targeting heat shock protein 90 and methods of use thereof
#1188Modified double-stranded RNA agents
#1189MODULATION OF APOLIPOPROTEIN C-III EXPRESSION
#1190COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#1191MODULATION OF APOLIPOPROTEIN CIII (APOCIII) EXPRESSION
#1192Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#1193PRECIPITATION OF POLYPEPTIDES BY APTAMER-POLYMER CONJUGATES
#1194Ruthenium-based photolinkers and methods of use
#1195Transcriptome in vivo analysis (TIVA) and transcriptome in situ analysis (TISA)
#1196Targeting ligands for therapeutic compounds
#1197Modulation of PTPRA to treat arthritis
#1198Compositions comprising an internalizing nucleic acid molecule, and their methods of use
#1199Polynucleotide agents targeting Serpinc1 (AT3) and methods of use thereof
#1200Antibody-siRNA conjugates and uses therefor